TCRX insider receives 1,000,000 shares in stock awards

By AlphaYouPublished Oct 2, 2026Form 4

Stocks in this disclosure

Reported activity

MacBeath Gavin

Reporting filer

MacBeath Gavin reported 1,000,000 shares of Voting Common Stock in TScan Therapeutics, Inc. as grants or awards dated 2026-10-01. The Form 4 was disclosed on Oct 2, 2026. These were stock awards, not open-market purchases.

Disclosed: Oct 2, 2026

Reported details

1 entry

All validated entries in this disclosure
Security	Owner	Date	Code	Action	Quantity	Price	Following holdings	Reporting delay	Filed terms and references
Voting Common Stock	MacBeath Gavin	2026-10-01	A	Grant or award	1000000	0.00	1,049,767	1 day	Filed terms security Title: Voting Common Stock transaction Date: 2026-10-01 transaction Form Type: 4 transaction Code: A equity Swap Involved: false id: F1 transaction Shares: 1000000 transaction Price Per Share: 0.00 transaction Acquired Disposed Code: A shares Owned Following Transaction: 1049767 direct Or Indirect Ownership: D

Voting Common Stock

Owner: MacBeath Gavin
Date: 2026-10-01
Code: A
Action: Grant or award
Quantity: 1000000
Price: 0.00
Following holdings: 1,049,767
Reporting delay: 1 day
Filed terms and references: Filed terms
security Title: Voting Common Stock
transaction Date: 2026-10-01
transaction Form Type: 4
transaction Code: A
equity Swap Involved: false
id: F1
transaction Shares: 1000000
transaction Price Per Share: 0.00
transaction Acquired Disposed Code: A
shares Owned Following Transaction: 1049767
direct Or Indirect Ownership: D

Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.

Filing context

Quantities and prices are shown in the units filed. No trade value is inferred from their product.
MacBeath Gavin: Chief Executive Officer, Director.
F1: 25% of the restricted stock units ("RSUs") shall vest on September 30, 2028, with the remaining 75% of the RSUs vesting on the earlier of (i) reporting of completion of the pivotal trial of TSC-101, or (ii) September 30, 2030, subject to continued service with the Issuer through the applicable vesting dates and the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan and the applicable award agreement.

Original sources

SEC ownership filing

Prepared automatically from public filing data. Report a correction.

Security

Owner

Date

Code

Action

Quantity

Price

Following holdings

Reporting delay

Filed terms and references

Voting Common Stock

MacBeath Gavin

2026-10-01

Grant or award

1000000

0.00

1,049,767

1 day

Filed terms

security Title: Voting Common Stock
transaction Date: 2026-10-01
transaction Form Type: 4
transaction Code: A
equity Swap Involved: false
id: F1
transaction Shares: 1000000
transaction Price Per Share: 0.00
transaction Acquired Disposed Code: A
shares Owned Following Transaction: 1049767
direct Or Indirect Ownership: D

Filing context

Quantities and prices are shown in the units filed. No trade value is inferred from their product.

MacBeath Gavin: Chief Executive Officer, Director.

F1: 25% of the restricted stock units ("RSUs") shall vest on September 30, 2028, with the remaining 75% of the RSUs vesting on the earlier of (i) reporting of completion of the pivotal trial of TSC-101, or (ii) September 30, 2030, subject to continued service with the Issuer through the applicable vesting dates and the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan and the applicable award agreement.